SBIR/STTR Small Business Innovation Programs

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are the federal government's primary mechanism for directing R&D funding to small, for-profit technology companies — and the largest source of early-stage federal grant money available to startups. Authorized under 15 U.S.C. § 638, the programs require 11 federal agencies (DOD, NIH, DOE, NASA, NSF, and others) to reserve fixed percentages of their extramural R&D budgets for small business awards: 3.2% for SBIR and 0.45% for STTR, totaling over $4 billion annually. The three-phase structure: Phase I ($150,000–$323,090 over 6–12 months) funds feasibility; Phase II ($1–2.15 million over 2 years) funds prototype development; Phase III (no SBIR funding cap) is commercialization, funded from the agency's mission budget. Unlike most federal contracts, SBIR/STTR recipients retain full intellectual property rights to the technology developed — making these awards strategically valuable not just for the non-dilutive funding but for preserving IP ownership that would be lost under a standard federal contract. Companies that have built on SBIR/STTR funding include many that became publicly traded — and the programs are a critical bridge between academic research and the commercial technology market.

Current Law (2026)

Legal Authority

• 15 U.S.C. § 638(a) — Policy (stimulate technological innovation; use small business to meet federal R&D needs; encourage participation by socially and economically disadvantaged small businesses; increase private-sector commercialization of innovations)
• 15 U.S.C. § 638(f) — SBIR program requirements (federal agencies with extramural R&D budgets exceeding $100 million must participate; 3.2% set-aside; three-phase structure)
• 15 U.S.C. § 638(e) — STTR requirements (federal agencies with extramural R&D budgets exceeding $1 billion must participate; 0.45% set-aside; requires formal partnership between small business and nonprofit research institution)
• 15 U.S.C. § 638(r) — Phase III (commercialization phase; no SBIR/STTR dollar limits; agencies and prime contractors may fund Phase III from non-SBIR budgets; data rights protections)

How It Works

SBIR and STTR are the federal government's primary programs for channeling R&D funding to small businesses — totaling over $4 billion annually and making the U.S. government the world's largest early-stage investor in technology commercialization. The programs run through a three-phase structure: Phase I ($150,000–$323,090 over 6–12 months) determines scientific/technical feasibility, with agencies typically funding 15–25% of proposals; Phase II ($1–2.15 million over 2 years) funds prototype development for Phase I awardees only; and Phase III (no SBIR dollar limits) is the commercialization stage where the small business secures private investment and government contracts to bring the innovation to market. The key difference between the two programs is collaboration: SBIR requires the small business to perform at least 2/3 of Phase I and 1/2 of Phase II research in-house, while STTR requires a formal research partnership with a nonprofit institution (university, federal lab, FFRDC) — with the small business performing at least 40% and the research institution at least 30% of the work. STTR explicitly channels technology transfer from universities and federal labs into the commercial marketplace.

To qualify, applicants must be U.S.-owned, for-profit, independently operated small businesses with 500 or fewer employees; for SBIR, the principal investigator must be primarily employed by the company during the project. A critical feature is data rights protection: SBIR/STTR awardees retain intellectual property rights to their innovations for 20 years, during which the government cannot disclose proprietary technical data to competitors or require licensing. The programs' track record is extensive — early SBIR funding supported Qualcomm, iRobot, Symantec, the cochlear implant, numerous cancer drugs, and advanced defense technologies. The 11 participating agencies include DOD (over $2B/year for defense and dual-use tech), NIH ($1.2B/year for biomedical and health tech), DOE, NASA, and NSF, with open solicitations at sbir.gov.

How It Affects You

If you're a small business founder or CEO pursuing early-stage technology funding: SBIR/STTR is the most important non-dilutive funding program in the U.S. — over $4 billion per year in grants that don't require equity or repayment. It pairs naturally with the equity and leverage lanes described in SBA Investment & Development Company Financing, and once you reach manufacturing scale, the broader manufacturing incentives framework can amplify the payoff. Phase I awards ($150,000–$323,090) are feasibility grants; Phase II awards ($1–$2.15 million) fund prototype development. Start by identifying which of the 11 participating SBIR agencies aligns with your technology: DOD is the largest (over $2B/year, covering defense and dual-use tech); NIH ($1.2B/year for biomedical and health tech); DOE (clean energy, materials); NASA (aerospace, earth observation); NSF (deep tech, computer science). Each agency posts open solicitations at sbir.gov — search by topic and apply to solicitations where your technology directly maps to the agency's stated needs. Phase I acceptance rates run 15–25%; success requires tailoring your proposal to the agency's mission, not just describing your technology. Eligibility: U.S.-owned, for-profit, ≤500 employees; the PI must be primarily employed by the company during the project.

If you're a university researcher or tech transfer professional: STTR (vs. SBIR) is specifically designed for university-industry collaboration — requiring a formal research partnership where the small business performs at least 40% of the work and your nonprofit research institution performs at least 30%. The small business applies and is the awardee, but your lab receives a share of the funding. Phase I STTR awards ($150,000–$323,090) are enough to establish the collaboration and prove feasibility; Phase II ($1–$2.15M) allows genuine prototype development. Key institutions — MIT, Stanford, Johns Hopkins, and others — have active programs helping their faculty spin out STTR-eligible companies. Your institution's Office of Technology Transfer should have a framework for establishing the required research agreements. STTR is particularly powerful in biomedical research (NIH is the largest STTR funder) and clean energy (DOE).

If you're a venture investor, angel investor, or startup accelerator: SBIR/STTR Phase I and II awards are validation signals — they indicate that a federal expert panel found the technology both technically feasible and mission-relevant. Companies that win Phase II awards have survived competitive review twice. Many VCs use SBIR/STTR awardee status as a screening filter for technical de-risking. Note that SBIR/STTR imposes data rights protections (currently 20 years) that prevent the government from disclosing awardees' proprietary technical data to competitors — protecting your portfolio companies' IP. After Phase II, the Phase III commercialization stage has no SBIR dollar limits; federal agencies can award Phase III contracts from mission budgets to awardees, providing revenue alongside private investment. The R&D tax credit provides additional tax benefits on qualified research expenditures — available in parallel with SBIR/STTR funding.

If you're looking to sell the resulting technology overseas: SBIR/STTR-funded innovations are natural candidates for the export promotion programs that help small technology firms reach foreign buyers. The data rights protections that let you keep your patent and trade secret position are also what make international licensing viable.

If you're a federal agency program manager or contracting officer: SBIR/STTR is your mechanism for engaging small businesses with innovative solutions to mission needs — and awarding Phase III contracts to SBIR/STTR awardees is faster and simpler than normal procurement. Under 15 U.S.C. § 638(r), agencies may sole-source Phase III contracts to SBIR/STTR awardees without competition — a significant acquisition advantage. DOD in particular has increased focus on transitioning SBIR/STTR innovations to programs of record through Phase III contracts. Your agency is required to allocate 3.2% of extramural R&D spending for SBIR and 0.45% for STTR — non-compliance is reported to Congress through SBA's annual SBIR report. Foreign ownership concerns have led to new restrictions: SBIR/STTR awardees with affiliations to countries of concern (China, Russia, Iran, North Korea) face enhanced scrutiny and potential disqualification under security provisions added in recent years.

State Variations

SBIR/STTR is exclusively federal. However:

• Many states offer matching funds or supplemental grants to SBIR/STTR awardees (e.g., state technology development programs)
• State economic development agencies often provide assistance with SBIR/STTR proposal writing and commercialization
• Some states offer tax incentives for SBIR/STTR awardees

Implementing Regulations

• 13 CFR Part 121 — SBA size standards determining small business eligibility for SBIR/STTR awards.
• SBA SBIR/STTR Policy Directives — Program requirements, agency set-aside percentages, and commercialization requirements are published as SBA directives rather than CFR.

32 CFR Part 37 — Technology Investment Agreements (DoD) (134 sections across 10 subparts): the DoD's regulatory framework for Technology Investment Agreements (TIAs) — a specialized funding instrument for applied research projects that advance important DoD objectives using non-traditional defense contractors, startups, and universities who are unwilling or unable to accept standard government contract terms. TIAs occupy a distinct regulatory space from SBIR/STTR awards: SBIR/STTR are competitive set-aside programs for small businesses; TIAs are negotiated agreements that DoD Components use when the standard FAR contracting framework would deter the best researchers from participating. Key provisions:

• § 37.100–37.115 — Purpose and general requirements (Subpart A): Part 37 establishes uniform policies for DoD's award and administration of TIAs; a TIA is an "other transaction" authority instrument under 10 U.S.C. § 4021 (formerly § 2371) — meaning it does not have to follow the Federal Acquisition Regulation, Cost Accounting Standards, Truth-in-Negotiations Act, or other standard procurement statutes that govern defense contracts; this regulatory flexibility is the primary reason researchers and commercial technology companies choose TIAs over contracts; recipients need not use government-approved accounting systems if they use commercial cost principles
• §§ 37.200–37.215 — Appropriate use (Subpart B): TIAs are appropriate when: (1) the research is "applied research" (not basic research, which uses grants, or development, which uses contracts); (2) it is important to incentivize nontraditional defense contractors who would not otherwise participate; (3) the agreement furthers substantial DoD objectives; (4) cost-sharing by the recipient or meaningful involvement of commercial sources is present; TIAs are NOT appropriate for development programs (those use standard procurement), testing and evaluation, or production activities
• §§ 37.300–37.315 — Two types of TIA (Subpart C): DoD Components may use either (1) expenditure-based TIAs, where DoD reimburses the recipient for allowable costs incurred (similar to a cost-reimbursement contract but without FAR requirements), or (2) fixed-support TIAs, where DoD provides a fixed amount of support and the recipient retains full flexibility in how it is spent (suitable when outcomes are well-defined but methods are not); fixed-support TIAs are simpler to administer but provide less cost visibility to the government
• §§ 37.400–37.450 — Competition (Subpart D): TIAs must be competed using merit-based selection; the DoD Component must publish a Broad Agency Announcement (BAA) describing the research need; proposals are evaluated on technical merit, qualifications, and reasonableness of costs; a recipient may not be selected for a TIA if the same work would normally be acquired through competitive sealed bidding or negotiation under the FAR — TIAs cannot be used to circumvent normal procurement competition
• §§ 37.500–37.530 — Pre-award business evaluation (Subpart E): before award, the DoD must evaluate the recipient's financial and management systems; unlike standard FAR procurement, DoD does not require DCAA (Defense Contract Audit Agency) audits or Cost Accounting Standards compliance — instead, the DoD agreements officer evaluates whether the recipient has adequate financial management systems for the proposed research; universities and small companies typically pass this evaluation with standard institutional financial controls
• §§ 37.600–37.650 — Award terms affecting finances (Subpart F): the award instrument specifies the recipient's cost-sharing obligations (if any), payment schedule, allowable cost principles (often Commercial Item cost principles rather than FAR Part 31), property rights disposition (recipients generally retain title to equipment purchased with TIA funds, unlike FAR contracts), and audit rights; intellectual property terms allow recipients to retain patent rights with DoD retaining a royalty-free license (similar to Bayh-Dole for federal grants)
• §§ 37.700–37.755 — Other administrative terms (Subpart G): reporting requirements (technical progress reports, financial reports); subcontracting with small businesses encouraged but not required through FAR flow-down clauses; civil rights and nondiscrimination requirements do apply; foreign national access restrictions for classified research; records retention (3 years minimum after final payment)

TIAs have been used by DARPA, the Army Research Laboratory, the Office of Naval Research, and the Air Force Research Laboratory to partner with commercial technology companies in Silicon Valley, Boston, and Austin who could not adapt their accounting and management systems to standard defense contract requirements. The technology investment agreement instrument has been particularly important for engaging companies working on cybersecurity, artificial intelligence, and advanced manufacturing technologies. The policy rationale is identical to the SBIR philosophy: getting the best researchers involved in defense problems sometimes requires accepting nonstandard terms rather than insisting on full FAR compliance.

Pending Legislation (119th Congress)

• HR 3169 (Rep. Velazquez, D-NY) — SBIR/STTR Reauthorization Act of 2025. Would raise agency funding floors, boost commercialization supports, add reporting and security safeguards, and extend pilots through 2030. Status: Introduced.
• HR 4775 (Rep. Tran, D-CA) — SBIR/STTR Foreign Interference Safeguard Act. Would bar SBIR/STTR awards to companies controlled by risky foreign entities and extend security screening to 2030. Status: Introduced.
• HR 7217 — SBIR Administrative Funding Act. Would raise SBIR/STTR admin funding, extend the funding window to 2030, and require major agencies to transfer at least 10% of related program funds. Status: Introduced.
• HR 3953 (Rep. Conaway, D-NJ) — SBIR/STTR Website Improvement Act. Would require SBIR and STTR databases to list subcontracted research institutions by name, location, and higher-education classification. Status: Introduced.
• S 3415 — Small Business Innovation Voucher Act of 2025. Would create an SBA innovation voucher program funding small businesses buying technical help from universities and research labs, authorizing $10 million/year for FY2026-2030. Status: Introduced.

Recent Developments

• SBIR/STTR permanently reauthorized April 14, 2026 via S.3971 (Small Business Innovation and Economic Security Act) after the longest lapse in the programs' history (Oct 1, 2025 – April 14, 2026). The law gradually raises set-asides to 7% for SBIR and 1% for STTR over seven years (from 3.2% and 0.45%) and creates new "Technology Commercialization Official" roles at participating agencies
• Concerns about foreign influence and technology transfer have led to new restrictions on SBIR/STTR awardees with foreign affiliations (particularly ties to China and Russia)
• DOD's SBIR/STTR portfolio has increased focus on rapid transition of innovations to military applications
• The "Phase III" commercialization gap — the challenge of moving from prototype to product — remains the program's biggest weakness
• NIH SBIR/STTR funds approximately $1.2 billion annually, making it the largest single source of SBIR funding